3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer -

Calcium + vitamin D doesn’t curb colorectal cancer risk

CancerFeb 16, 06

In a large study of postmenopausal women, daily supplementation of calcium with vitamin D for 7 years did not reduce the risk of colorectal cancer, doctors report in The New England Journal of Medicine this week. However, a beneficial effect may be become apparent with longer follow-up, the authors note.

Past studies have linked calcium and vitamin D use with a reduced risk of colorectal cancer and, in polyp-prevention trials, this combination seemed to help prevent polyp recurrence. Whether this dietary intervention could actually help prevent colorectal cancer, however, was unclear.

To investigate, Dr. Jean Wactawski-Wende, from SUNY University at Buffalo in New York, and colleagues assessed the outcomes of 36,282 postmenopausal women who participated in a study in which they received calcium 500 mg with vitamin D 200 IU or matching placebos twice daily for 7 years.

During follow-up, the number of women who developed colorectal cancer was nearly the same in each group, hovering around 161.

Moreover, the tumors that developed in each group were similar in appearance and stage. Likewise, colorectal-cancer screening and abdominal symptoms were comparable in each group.

The investigators reason that the “long latency associated with the development of colorectal cancer, in concert with the 7-year duration of the trial, may have contributed to” the null finding.

In a related editorial, Dr. Michele R. Forman and Dr. Bernard Levin, from the M. D. Anderson Cancer Center in Houston, note that the doses of these substances “may have been too low to achieve the desired effect.”

SOURCE: The New England Journal of Medicine, February 16, 2006



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site